Abstract: Provided are a program, an information processing device, a method, and a system that allow properties of an organized party to be easily grasped. An information processing device 10 is an information processing device for executing a game and includes: a setting unit 231 for setting two or more game media on a deck with which indicator information is associated; an indicator-information-point calculation unit 232 for determining points for each item of the indicator information on the basis of predetermined data associated with the game media; and an indicator-information determination unit 233 for determining the indicator information to be displayed on a game screen on the basis of the points for each item of the indicator information obtained by the indicator-information-point calculation unit 232 and associating the determined indicator information with the deck.

Abstract: A travel route selection system for an electric truck includes a map information acquisition unit that acquires map information including transport route information on transport routes. An electric power consumption map storage unit is adapted to pre-store a stop-time electric power consumption map used to estimate electric power consumption during the stoppage time during which the electric truck stops for a predetermined period with high-voltage equipment kept in operating state. A stoppage time estimation unit estimates stoppage time on each transportation route. An electric power consumption estimation unit estimates the electric power consumption on each of the transportation routes based on the stoppage time estimated by the stoppage time estimation unit as well as on the stop-time electric power consumption map. An optimal route selection unit selects an optimal route based on fundamental information including information on the amount of electric power consumption of each of the transport routes.

Abstract: A vehicular door device causes a door to perform an opening-closing operation, based on an operation of a link mechanism formed of first and second link arms. Further, the first link arm is provided with a hand placement portion that rotates integrally with the first link arm. Then, the vehicular door device is configured in such a way that the first link arm supports a load applied to the hand placement portion.

Abstract: A travel route selection system for an electric truck includes a map information acquisition unit that acquires map information including transport route information on transport routes. An electric power consumption map storage unit is adapted to pre-store a stop-time electric power consumption map used to estimate electric power consumption during the stoppage time during which the electric truck stops for a predetermined period with high-voltage equipment kept in operating state. A stoppage time estimation unit estimates stoppage time on each transportation route. An electric power consumption estimation unit estimates the electric power consumption on each of the transportation routes based on the stoppage time estimated by the stoppage time estimation unit as well as on the stop-time electric power consumption map. An optimal route selection unit selects an optimal route based on fundamental information including information on the amount of electric power consumption of each of the transport routes.

Abstract: A travel route selection system includes a map information acquisition unit for acquiring map information including transportation route information about a plurality of transportation routes; an electric power consumption map storage unit adapted to prestore a drive-time electric power consumption map used to estimate electric power consumption of an electric truck running on a predetermined route at a predetermined average vehicle speed; an average vehicle speed estimation unit for estimating an average vehicle speed during running on each of the plurality of transportation routes; an electric power consumption estimation unit for estimating electric power consumption on each of the plurality of transportation routes based on the average vehicle speed and on the electric power consumption map; and an optimal route selection unit for selecting an optimal route based on fundamental information including information about the electric power consumption on each of the plurality of transportation routes.

Abstract: Methods of treating osteoporosis by administering synergistically effective amounts of genistein and a bisphosphonate, or pharmaceutically acceptable salts thereof.

Abstract: A method for treating a disease associated with transcription activation by NF-?B by administering a composition for inhibiting transcription activation by NF-?B to a patient in need of treatment of the disease. The composition contains a fraction having a molecular weight of 3,000 or less obtained by purifying a water extract of Sargassum horneri as an active ingredient.

Abstract: Pharmaceutical formulations of ?-Caryophyllene, and methods of supporting and promoting bone health using ?-Caryophyllene, are described.

Abstract: A travel route selection system includes a map information acquisition unit for acquiring map information including transportation route information about a plurality of transportation routes; an electric power consumption map storage unit adapted to prestore a drive-time electric power consumption map used to estimate electric power consumption of an electric truck running on a predetermined route at a predetermined average vehicle speed; an average vehicle speed estimation unit for estimating an average vehicle speed during running on each of the plurality of transportation routes; an electric power consumption estimation unit for estimating electric power consumption on each of the plurality of transportation routes based on the average vehicle speed and on the electric power consumption map; and an optimal route selection unit for selecting an optimal route based on fundamental information including information about the electric power consumption on each of the plurality of transportation routes.

Abstract: Provided is a pharmaceutical formulation and a method associated therewith for treating inflammation. The pharmaceutical formulation includes therapeutically effective amounts of sesquiterpenes such as ?-caryophyllene and two flavonoids. The two flavonoids include baicalin and catechin.

Abstract: An adhesive with improved heat stability is provided. The adhesive includes an ethylene??-olefin copolymer (A) having a number-average molecular weight of 5000 to 100000 in terms of polystyrene as measured by gel permeation chromatography and a density of 860 to 970 kg/m3, wherein in the ethylene??-olefin copolymer (A), the total number of vinyl-type double bond, vinylidene-type double bond, 2-substituted olefin-type double bond and 3-substituted olefin-type double bond is less than 0.5 per 1000 carbon atoms as measured by 1H-NMR.

Abstract: Provided is a pharmaceutical formulation and a method associated therewith for treating inflammation. The pharmaceutical formulation includes therapeutically effective amounts of sesquiterpenes such as ?-caryophyllene and two flavonoids. The two flavonoids include baicalin and catechin.

Abstract: Provided is a pharmaceutical formulation and a method associated therewith for treating inflammation. The pharmaceutical formulation includes therapeutically effective amounts of sesquiterpenes such as ?-caryophyllene and two flavonoids. The two flavonoids include baicalin and catechin.

Abstract: An object of the invention is to provide compositions which have low-temperature heat sealing properties, are free from stickiness, may achieve a heat seal strength controlled within a certain definite range when heat sealing takes place at low temperatures, have small changes in heat seal strength with time, and are such that in the packaging applications, the strength required to open the packages may be easily controlled within a certain definite range, and high-performance packages may be designed. The invention resides in a 1-butene.?-olefin copolymer composition including 99 to 1 parts by mass of at least one olefin polymer (X) selected from propylene polymers (X-1) and ethylene polymers (X-2), and 1 to 99 parts by mass of a 1-butene.?-olefin copolymer (Y) containing 0.1 to 30 mol % of one or more ?-olefins selected from ?-olefins and having a molecular weight distribution (Mw/Mn) of 1.0 to 3.5 [wherein the total of (X) and (Y) in the composition is 100 parts by mass].

Abstract: Means for solving the problems The thermoplastic resin composition (X1) of the present invention comprises (A1), (B1), (C1), and optionally (D1) below: 1 to 90 wt % of an isotactic polypropylene (A1); 9 to 98 wt % of a propylene/ethylene/?-olefin copolymer (B1) containing 45 to 89 mol % of propylene-derived structural units, 10 to 25 mol % of ethylene-derived structural units, and optionally, 0 to 30 mol % of C4-C20 ?-olefin-derived structural units (a1); 1 to 80 wt % of a styrene-based elastomer (C1); and 0 to 70 wt % of an ethylene/?-olefin copolymer (D1) whose density is in the range of 0.850 to 0.910 g/cm3, wherein (A1)+(B1)+(C1)+(D1)=100 wt %.

Abstract: Means for solving the problems The thermoplastic resin composition (X1) of the present invention comprises (A1), (B1), (C1), and optionally (D1) below: 1 to 90 wt % of an isotactic polypropylene (A1); 9 to 98 wt % of a propylene/ethylene/?-olefin copolymer (B1) containing 45 to 89 mol % of propylene-derived structural units, 10 to 25 mol % of ethylene-derived structural units, and optionally, 0 to 30 mol % of C4-C20 ?-olefin-derived structural units (a1); 1 to 80 wt % of a styrene-based elastomer (C1); and 0 to 70 wt % of an ethylene/?-olefin copolymer (D1) whose density is in the range of 0.850 to 0.910 g/cm3, wherein (A1)+(B1)+(C1)+(D1)=100 wt %.

Abstract: It is to provide an agent for suppressing proliferation and/or inducing apoptosis of cancer cells that can be used for the treatment and chemoprophylaxis of cancer, wherein the agent is easily accessible and ingestible in daily dietary life and is prepared using a naturally-derived ingredient with reduced side effects, and a method for suppressing proliferation and/or inducing apoptosis of cancer cells in a subject in need thereof, and the like. By administering an agent for suppressing proliferation and/or inducing apoptosis of cancer cells comprising Sargassum horneri or a processed product thereof to a subject in need thereof, the proliferation of cancer cells can be inhibited and apoptosis of cancer cells can be induced in the subject.

Abstract: Means for solving the problems The thermoplastic resin composition (X1) of the present invention comprises (A1), (B1), (C1), and optionally (D1) below: 1 to 90 wt % of an isotactic polypropylene (A1); 9 to 98 wt % of a propylene/ethylene/?-olefin copolymer (B1) containing 45 to 89 mol % of propylene-derived structural units, 10 to 25 mol % of ethylene-derived structural units, and optionally, 0 to 30 mol % of C4-C20 ?-olefin-derived structural units (a1); 1 to 80 wt % of a styrene-based elastomer (C1); and 0 to 70 wt % of an ethylene/?-olefin copolymer (D1) whose density is in the range of 0.850 to 0.910 g/cm3, wherein (A1)+(B1)+(C1)+(D1)=100 wt %.

Abstract: Pharmaceutical formulations of ?-Caryophyllene, and methods of supporting and promoting bone health using ?-Caryophyllene, are described.

Abstract: It is to provide an agent for suppressing proliferation and/or inducing apoptosis of cancer cells that can be used for the treatment and chemoprophylaxis of cancer, wherein the agent is easily accessible and ingestible in daily dietary life and is prepared using a naturally-derived ingredient with reduced side effects, and a method for suppressing proliferation and/or inducing apoptosis of cancer cells in a subject in need thereof, and the like. By administering an agent for suppressing proliferation and/or inducing apoptosis of cancer cells comprising Sargassum horneri or a processed product thereof to a subject in need thereof, the proliferation of cancer cells can be inhibited and apoptosis of cancer cells can be induced in the subject.